Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This oral tablet is a combination nutraceutical product manufactured by Saltvae Pharmaceuticals, primarily indicated for the management of Polycystic Ovary Syndrome (PCOS) and associated female infertility. The formulation combines five active ingredients: myo-inositol, which acts as an insulin sensitizer to improve ovulation and egg quality; L-arginine, which serves as a precursor to nitric oxide to enhance pelvic blood flow; L-carnitine, which supports cellular energy metabolism; folic acid, essential for DNA synthesis and homocysteine regulation; and selenium, which provides antioxidant support. Together, these components target insulin resistance, metabolic dysfunction, and oxidative stress to improve reproductive outcomes and reduce the risk of gestational diabetes in women with PCOS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myo-inositol + L-arginine + L-carnitine + folic acid + selenium.